Enfortumab + pembrolizumab showed improved responses over chemo in untreated la/mUC, per updated EV-302 results.
Advanced Urothelial Carcinoma
Advertisement
Latest News
Nivolumab + ipilimumab provided a favorable landmark OS in cisplatin-ineligible patients with unresectable or metastatic UC.
Researchers evaluated the use of disitamab vedotin with toripalimab in improving survival in patients with advanced UC.
Consolidative surgery after EVP shows feasibility and strong pathologic response rates in advanced urothelial carcinoma.
Drs. Koshkin and Nizam discuss how a longer treatment-free interval may predict benefit from pembrolizumab rechallenge.
Drs. Koshkin and Nizam break down recent research on pembro in patients with la/mUC who responded to first-course pembro.
Dr. Grivas provides perspective of the long-term outcomes from the JAVELIN Bladder 100 trial as pertaining to older patients.
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
At 12 months, the OS rate for patients who received treatment with ipilimumab plus nivolumab was superior to SOC.
The Two Onc Docs review QOL related to doublet ADT with darolutamide, niraparib with abiraterone for mCSPC, and more.
The Two Onc Docs review the 5-year follow-up data on adjuvant pembro and a final analysis on ipi/nivo for metastatic disease.
The Two Onc Docs weigh IO for BCG-refractory NMIBC, ctDNA monitoring for patients receiving gem/cis for MIBC, and more.
Dr. Machaalani highlights his study that evaluated the association between circulating KIM-1 and mRCC tumor biology.
Dr. James showcases an MMAI model to identify benefit from 2nd-generation ARPIs in hr/nm PCa patients from STAMPEDE.
Advertisement
Section Editor
Karine Tawagi, MDDepartment of Medicine | University of Illinois
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.